losartan potassium and hydrochlorothiazide tablet
aidarex pharmaceuticals llc - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - losartan potassium 100 mg - when used in pregnancy during the second and third trimesters, drugs that act directly on the reninangiotensin system can cause injury and even death to the developing fetus. when pregnancy is detected, losartan potassium and hydrochlorothiazide should be discontinued as soon as possible. see warnings: fetal/neonatal morbidity and mortality . losartan potassium and hydrochlorothiazide tablets usp are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see clinical pharmacology: pharmacodynamics and clinical effects, and dosage and administration ). losartan potassium and hydrochlorothiazide tablets usp are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply t
losartan potassium tablet
stat rx usa llc - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 100 mg - hypertension losartan potassium tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents, including diuretics. hypertensive patients with left ventricular hypertrophy losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see and , precautions race , clinical pharmacology , , .) pharmacodynamics and clinical effectsreduction in the risk of strokerace in 2 patients nephropathy type diabetic losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 dia
losartan potassium and hydrochlorothiazide tablet
rebel distributors corp - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - losartan potassium 100 mg - hypertension losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see clinical pharmacology, pharmacodynamics and clinical effects, and dosage and administration). hypertensive patients with left ventricular hypertrophy losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see precautions, race, clinical pharmacology, pharmacodynamics and clinical effects, losartan potassium, reduction in the risk of stroke, race, and dosage and administration). losartan potassium and hydrochlorothiazide tablets are contraindicated in patie
losartan potassium and hydrochlorothiazide tablet, film coated
stat rx usa llc - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - losartan potassium 100 mg - hypertension losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see clinical pharmacology , pharmacodynamics and clinical effects, and dosage and administration ). hypertensive patients with left ventricular hypertrophy losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients (see precautions , race, clinical pharmacology , pharmacodynamics and clinical effects, losartan potassium, reduction in the risk of stroke, race, and dosage and administration ). losartan potassium and hydrochlorothiazide tablets are contraindi
losartan potassium tablet
st marys medical park pharmacy - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 50 mg - hypertension losartan potassium tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents, including diuretics. hypertensive patients with left ventricular hypertrophy losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see precautions, race and clinical pharmacology, pharmacodynamics and clinical effects, reduction in the risk of stroke, race.) nephropathy in type 2 diabetic patients losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. in this population, losartan potassium tablets reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end
losartan potassium- losartan potassium tablet, film coated
sandoz inc. - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 25 mg - losartan potassium tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents, including diuretics. losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see precautions, race and clinical pharmacology, pharmacodynamics and clinical effects, reduction in the risk of stroke, race.) losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. in this population, losartan potassium tablets reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see clinical pharmacology, pharmacodynam
losartan potassium and hydrochlorothiazide- losartan potassium and hydrochlorothiazide tablet, film coated
sandoz inc. - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - losartan potassium 50 mg - losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see clinical pharmacology, pharmacodynamics and clinical effects and dosage and administration). losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see precautions, race, clinical pharmacology, pharmacodynamics and clinical effects, losartan potassium, reduction in the risk of stroke, race, and dosage and administration.) losartan potassium and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product. because of the hydroch
losartan potatssium tablet
new horizon rx group, llc - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 50 mg - hypertension: losartan potassium tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents, including diuretics. hypertensive patients with left ventricular hypertrophy: losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients (see precautions, raceand clinical pharmacology, pharmacodynamics and clinical effects, reduction in the risk of stroke, race). nephropathy in type 2 diabetic patients losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥ 300 mg/g) in patients with type 2 diabetes and a history of hypertension. in this population, losartan potassium reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage
losartan potassium and hydrochlorothiazide tablet
dispensing solutions, inc. - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - losartan potassium 100 mg - hypertension losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see clinical pharmacology, pharmacodynamics and clinical effects, and dosage and administration). hypertensive patients with left ventricular hypertrophy losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see precautions, race, clinical pharmacology, pharmacodynamics and clinical effects, losartan potassium, reduction in the risk of stroke, race, and dosage and administration). losartan potassium and hydrochlorothiazide tablets are contraindicat
losartan krka 100 mg film-coated tablets
krka, d.d., novo mesto - losartan potassium - film-coated tablet - 100 milligram(s) - angiotensin ii antagonists, plain; losartan